| Literature DB >> 22911665 |
Janine L Bakker1, Saskia E van Mil, Gerry Crossan, Nelly Sabbaghian, Kim De Leeneer, Bruce Poppe, Muriel Adank, Hans Gille, Henk Verheul, Hanne Meijers-Heijboer, Johan P de Winter, Kathleen Claes, Marc Tischkowitz, Quinten Waisfisz.
Abstract
SLX4/FANCP is a recently discovered novel disease gene for Fanconi anemia (FA), a rare recessive disorder characterized by chromosomal instability and increased cancer susceptibility. Three of the 15 FA genes are breast cancer susceptibility genes in heterozygous mutation carriers--BRCA2, PALB2, and BRIP1. To investigate if defects in SLX4 also predispose to breast cancer, the gene was sequenced in a cohort of 729 BRCA1/BRCA2-negative familial breast cancer cases. We identified a single splice site mutation (c.2013+2T>A), which causes a frameshift by skipping of exon 8. We also identified 39 missense variants, four of which were selected for functional testing in a Mitomycin C-induced growth inhibition assay, and appeared indistinguishable from wild type. Although this is the first study that describes a truncating SLX4 mutation in breast cancer patients, our data indicate that germline mutations in SLX4 are very rare and are unlikely to make a significant contribution to familial breast cancer.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22911665 DOI: 10.1002/humu.22206
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878